These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 8963784)
1. [Immunosuppression and the problems in homologous bone marrow transplantation]. Yabe H; Kato S Nihon Rinsho Meneki Gakkai Kaishi; 1995 Dec; 18(6):681-2. PubMed ID: 8963784 [No Abstract] [Full Text] [Related]
2. Role of immunosuppressive drugs for prevention of graft-v-host disease after human HLA matched bone marrow transplantation. Gluckman E; Devergie A; Lokiec F; Traineau R; Cosset JM; Lemercier N; Varrin F; Cavazzana M; de Castro H; Meletis J Transplant Proc; 1987 Dec; 19(6 Suppl 7):61-5. PubMed ID: 3321648 [No Abstract] [Full Text] [Related]
3. Cyclosporine does not prevent in vivo expression of T cell activation antigens following allogeneic bone marrow transplantation. Forman SJ; Gallagher MT; Zaia JA; Wright C; Blume KG Transplantation; 1984 Feb; 37(2):219-20. PubMed ID: 6420961 [No Abstract] [Full Text] [Related]
4. Regeneration of genetically restricted immune functions after human bone marrow transplantation: influence of four different strategies for graft-v-host disease prophylaxis. Donnenberg AD; Hess AD; Duff SC; Bright EC; Noga SJ; Rowley SD; Saral R; Santos GW Transplant Proc; 1987 Dec; 19(6 Suppl 7):144-52. PubMed ID: 3321641 [No Abstract] [Full Text] [Related]
5. The problems and practice of bone marrow transplantation in man: the severe combined immunodeficiency syndrome as the ideal model. Levey RH Transplant Proc; 1972 Dec; 4(4):565-6. PubMed ID: 4405148 [No Abstract] [Full Text] [Related]
6. Lymphocyte reconstitution after allogeneic bone marrow transplantation in a previously thymectomized patient--no evidence of extrathymic T-cell maturation. Giebel S; Dziaczkowska J; Wysoczanska B; Wojnar J; Krawczyk-Kulis M; Lange A; Holowiecki J Bone Marrow Transplant; 2007 Oct; 40(7):705-6. PubMed ID: 17680024 [No Abstract] [Full Text] [Related]
7. Cyclosporin a: a new era in organ transplantation. DeBakey ME Compr Ther; 1984 Feb; 10(2):7-15. PubMed ID: 6368108 [No Abstract] [Full Text] [Related]
8. CD34+ stem cell augmentation of elutriated allogeneic bone marrow grafts: results of a phase II clinical trial of engraftment and graft-versus-host disease prophylaxis in high-risk hematologic malignancies. O'Donnell PV; Jones RJ; Vogelsang GB; Seber A; Ambinder RF; Flinn I; Miller C; Marcellus DC; Griffin C; Abrams R; Braine HG; Grever M; Hess AD; Piantadosi S; Noga SJ Bone Marrow Transplant; 1998 Nov; 22(10):947-55. PubMed ID: 9849691 [TBL] [Abstract][Full Text] [Related]
9. [Immunologic problems in allogenic and autologous bone marrow transplantation]. Schwenke H; Helbig W; Kubel M; Schultze W Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(2):217-23. PubMed ID: 6208106 [No Abstract] [Full Text] [Related]
10. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft. Herrera C; Torres A; GarcĂa-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557 [TBL] [Abstract][Full Text] [Related]
11. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft. Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494 [TBL] [Abstract][Full Text] [Related]
12. Modulation of graft-versus-host disease: role of regulatory T lymphocytes. Hess AD Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 2):13-21. PubMed ID: 16399597 [TBL] [Abstract][Full Text] [Related]
13. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation. Li JM; Waller EK Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532 [TBL] [Abstract][Full Text] [Related]
14. Immunoregulation rather than immunosuppression for prevention and treatment of autoimmune disorders. Slavin S Transplant Proc; 1996 Dec; 28(6):3021-2. PubMed ID: 8962172 [No Abstract] [Full Text] [Related]
15. Safe and efficacious allogeneic bone marrow transplantation for nonmalignant disorders using partial T cell depletion and no posttransplantation graft-versus-host-disease prophylaxis. Elhasid R; Arush MB; Zaidman I; Leiba R; Barak AB; Postovsky S; Haddad N; Katz T; Pollack S; Sami I; Gidoni O; Rubin D; Mandel H; Attias D; Reisner Y; Etzioni A; Rowe JM Biol Blood Marrow Transplant; 2007 Mar; 13(3):329-38. PubMed ID: 17317586 [TBL] [Abstract][Full Text] [Related]
17. Induction of tolerance with cyclosporin A. Tutschka PJ Prog Clin Biol Res; 1986; 224():209-26. PubMed ID: 2948193 [No Abstract] [Full Text] [Related]
18. Bone marrow transplantation: an option for children with acute leukemia. Stream P; Harrington E; Clark M Cancer Nurs; 1980 Jun; 3(3):195-9. PubMed ID: 6991098 [No Abstract] [Full Text] [Related]
19. A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial. Sao H; Kitaori K; Kasai M; Shimokawa T; Kato C; Yamanishi H; Ueda R; Morishima Y Int J Hematol; 1999 Jan; 69(1):27-35. PubMed ID: 10641440 [TBL] [Abstract][Full Text] [Related]